Other

Braintree Laboratories, Inc.

Nabi Biopharmaceuticals, Inc.

Robert M Raleigh

Edmund V Dennett, Jr

Bruce H Aronson

Russell W Pelham

Mark vB Cleveland

Mark Vb Cleveland

Vivian Caballero

Disclosed herein are formulations comprising lactitol for the treatment of chronic idiopathic constipation. As disclosed herein, the formulations are administered after or during a meal to improve the pharmacokinetics of the formulation. In particular, administration of the formulation after or during a meal decreases the absorption of lactitol and reduces the AUC.

Method of administering lactitol to reduce plasma concentration of lactitol

A composition for inhibiting gastrointestinal absorption of phosphorous in an individual. The composition includes a quantity of calcium acetate sufficient to bind the phosphorous in the gastrointestinal tract of the individual. The calcium acetate has a bulk density of between 0.50 kg/L and 0.80 kg/L and is dimensioned to form a caplet for fitting within a capsule in a manner that optimizes the volume of the capsule. Also provided is a method for administering the calcium acetate composition of the present invention to an individual to reduce phosphorous absorption by binding with the phosphorous in their gastrointestinal tract.

Encapsulated calcium acetate caplet and a method for inhibiting gastrointestinal phosphorous absorption

Growing community of inventors

Pembroke, MA, United States of America

Robert M Raleigh